指南与共识冠心病

经皮冠状动脉介入治疗高出血风险患者的定义:ARC-HBR共识文件

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.
指南 / 共识 · Eur Heart J · 2019-01-01

该共识由ARC-HBR联合美国、亚洲和欧洲的研究机构、监管机构及医师科学家制定,基于现有证据提出高出血风险患者的统一定义,旨在为经皮冠状动脉介入治疗相关临床试验和临床决策提供一致性标准。

要点

  • ARC-HBR提出首个经皮冠状动脉介入治疗高出血风险患者的实用共识定义。
  • 该定义基于现有证据综述,旨在统一临床试验人群并辅助临床决策。
  • 共识由31名成员参与,包括FDA和日本PMDA代表。

核心结论

  • ARC-HBR共识文件提出了经皮冠状动脉介入治疗高出血风险患者的统一定义,旨在为临床试验和临床决策提供一致性。

研究设计与样本

  • ARC-HBR是由美国、亚洲和欧洲的研究组织、监管机构及医师科学家组成的合作组织,专注于经皮冠状动脉介入治疗相关出血。

主要发现

  • 基于现有证据综述,制定了高出血风险患者的共识定义。

临床怎么用

  • 该定义旨在为临床试验中定义高出血风险人群提供一致性,并补充临床决策和监管审评。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention-related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to complement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing percutaneous coronary intervention.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019. PMID: 31116395. doi:10.1093/eurheartj/ehz372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。